middle.news
Aroa Biosurgery Posts 23% Revenue Growth and Positive EBITDA in FY26
11:43am on Tuesday 30th of June, 2026 AEST
•
Healthcare
Read Story
Aroa Biosurgery Posts 23% Revenue Growth and Positive EBITDA in FY26
11:43am on Tuesday 30th of June, 2026 AEST
Key Points
Total revenue up 23% to NZ$103.9 million
Myriad product sales surge 54%
Second consecutive year of positive normalised EBITDA at NZ$12.6 million
Symphony trial meets primary endpoint for diabetic foot ulcers
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aroa Biosurgery (ASX:ARX)
OPEN ARTICLE